Peritonitis clinical trials at UC Davis
1 research study open to eligible people
open to eligible people ages 18-80
Phase 2 multicenter study to be conducted in up to 50 qualified participating sites in the United States to assess the efficacy and safety of Reltecimod vs placebo in patients with abdominal sepsis-associated Stage 2/3 AKI.
Sacramento, California and other locations